Rezim Tablet 60 mg contains Resmetirom, an innovative thyroid hormone receptor‑β (THR‑β) agonist developed to target metabolic disorders associated with liver fat accumulation. This medication is most prominently used for the management of non‑alcoholic steatohepatitis (NASH) — a progressive form of non‑alcoholic fatty liver disease (NAFLD) characterized by liver inflammation, fat buildup, and fibrosis (scarring).

Rezim acts by selectively activating the thyroid hormone receptor‑β in liver tissue. This activation stimulates metabolic pathways that increase fat breakdown, improve lipid profiles, and reduce inflammation and fibrosis in the liver. Because of its targeted action, Rezim helps address both the underlying causes and clinical complications of NASH, making it a promising therapy for patients with this condition.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Resmetirom 60 mg

Indications

Rezim Tablet 60 mg is indicated for:

• Management of non‑alcoholic steatohepatitis (NASH) in adults

• Reduction of liver fat content in patients with NAFLD/NASH

• Improvement of metabolic parameters associated with liver disease (e.g., dyslipidemia)

• Adjunctive treatment for adults with NASH and liver fibrosis

• Supportive therapy in metabolic liver disorders as prescribed by a physician

Mechanism of Action

Resmetirom selectively agonizes thyroid hormone receptor‑β located predominantly in the liver. Key effects include:

• Increased hepatic fat breakdown (lipolysis): By activating metabolic pathways, Resmetirom enhances the liver’s ability to use and clear fat.

• Improved lipid profile: The therapy lowers levels of bad cholesterol (LDL) and triglycerides while supporting overall lipid metabolism.

• Anti‑inflammatory effects: Reduced liver inflammation contributes to slower disease progression.

• Antifibrotic benefits: May help reduce or stabilize liver fibrosis, a major predictor of long‑term outcomes in NASH.

This mechanism allows Rezim to address the root metabolic disturbances in NASH rather than only targeting symptomatic relief.

Dosage and Administration

• The typical recommended dose is 60 mg once daily, taken orally with or without food.

• Swallow the tablet whole with water; do not crush or chew unless directed by a physician.

• Treatment duration varies according to clinical response and disease severity; long‑term therapy may be required under medical supervision.

• Regular monitoring of liver function tests, lipid profile, and metabolic parameters is recommended during treatment.

Precautions and Warnings

• Use with caution in patients with thyroid disorders and known hormonal imbalances.

• Not recommended for patients with severe liver impairment unless closely monitored by a specialist.

• Inform your healthcare provider of all concurrent medications to avoid potential interactions.

• Not advised for use during pregnancy or breastfeeding unless benefits outweigh risks — seek medical counsel.

• Regular follow‑up tests may be required to assess liver enzyme levels and therapeutic effectiveness.

Possible Side Effects

Rezim Tablet 60 mg is generally well tolerated, but some patients may experience:

• Mild gastrointestinal symptoms (e.g., nausea, abdominal discomfort)

• Headache

• Fatigue or dizziness

• Changes in thyroid hormone levels (rare)

• Alterations in lipid profiles (monitored during therapy)

Serious adverse effects are uncommon but require medical attention if they occur.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store below 30°C in a cool, dry place.

• Protect from direct sunlight and moisture.

• Keep out of reach of children.

Conclusion

Rezim Tablet 60 mg (Resmetirom) is a specialized therapy designed to target the underlying metabolic dysfunction seen in non‑alcoholic steatohepatitis (NASH). By selectively activating thyroid hormone receptor‑β in the liver, it promotes fat breakdown, improves lipid metabolism, reduces inflammation, and may slow fibrosis progression. When used under proper medical supervision, Rezim offers an effective option in the management of this chronic liver condition.